TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2026

TOGETHER WITH LIMITED REVIEW REPORT

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E)

Interim Condensed Consolidated Financial Statements
For the Three-Month And Six-Month Periods Ended 30 June 2026

Table of Contents **Page**

ALLIED FOR ACCOUNTING & AUDITING
P.O. Box 20, Katameya
Podium 1, Building No. P4
Cairo Festival City
New Cairo, Arab Republic of Egypt

Tel: +202 2726 0260
Fax: +202 2726 0100
cairo.office@eg.ey.com
https://www.ey.com

Translation of consolidation financial statements
Originally issued in Arabic

REPORT ON REVIEW OF INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
TO THE BOARD OF DIRECTORS OF
TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

Introduction

We have reviewed the accompanying interim condensed consolidated financial position of **Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E) ("The Company")** as of 30 June 2026, as well as the related interim condensed consolidated statements of profit or loss, Comprehensive income for the three and six months periods ended 30 June 2026, and the related interim consolidated changes in equity and cash flows for the six months period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with Egyptian Accounting Standards No.(30) "Interim Financial Statements". Our responsibility is to express a conclusion on these Interim condensed consolidated financial statements based on our review.

Scope of Review

We conducted our review in accordance with Egyptian Standard on Review Engagements No. 2410, "Review of interim condensed consolidated Financial Statements Performed by the Independent Auditor of the Entity." A review of interim condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Egyptian Standards on Auditing. Consequently, it does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim condensed consolidated financial statements does not give a true and fair view, in all material respects, of the interim condensed consolidated financial position of the entity as at 30 June 2026, and of its financial performance for the three and six months periods ended on 30 June 2026 and its interim condensed consolidated cash flows for the six months then ended in accordance with Egyptian Accounting Standards No.(30) "Interim Financial Statements".

Auditor

Ahmed

Ahmed Amin Hafez
(RAA 20904)
FESAA
FRA Register No. (403)

Allied For Accounting & Auditing
A Member of
Ernst & Young Global
المتضامنون للمحاسبة والمراجعة

Cairo: 13 August 2026

Tenth Of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 June 2026

	Notes	*30 June 2026 EGP*	*31 December 2025 EGP*
ASSETS			
Non-current assets			
Fixed assets and assets under construction	(5)	**720,874,626**	719,992,976
Right of use assets	(6-A)	**65,009,695**	72,155,756
Intangible assets	(7)	**1,100,550,310**	1,110,797,408
Total non-current assets		**1,886,434,631**	1,902,946,140
Current assets			
Inventories	(8)	**1,011,080,072**	1,031,465,091
Trade and notes receivable	(9)	**2,458,081,046**	2,115,289,920
Due from related parties	(32)	**25,500**	25,500
Prepayments and other receivables	(10)	**176,715,112**	157,783,150
Cash on hand and at banks	(11)	**104,847,118**	36,178,688
Other assets	(12)	**-**	93,839,078
Total current assets		**3,750,748,848**	3,434,581,427
TOTAL ASSETS		**5,637,183,479**	5,337,527,567
EQUITY AND LIABILITIES			
Equity			
Paid up capital	(15)	**508,204,334**	500,000,000
Legal reserve		**250,000,000**	250,000,000
General reserve	(16)	**255,792,295**	255,792,295
Share based payments reserve	(18)	**38,177,534**	12,762,534
Other reserves		**278,952**	278,952
Retained earnings		**1,278,531,120**	1,148,943,876
Total equity of parent company		**2,330,984,235**	2,167,777,657
Non-controlling interest		**43,332,697**	42,122,663
Total equity		**2,374,316,932**	2,209,900,320
LIABILITIES			
Non-current liabilities			
Lease liabilities – noncurrent portion	(6-B)	**75,305,121**	75,460,824
Deferred tax liabilities	(29)	**80,901,263**	68,571,527
Total non-current liabilities		**156,206,384**	144,032,351
Current liabilities			
Provisions	(13)	**24,970,947**	14,970,947
Credit facilities	(19)	**2,275,568,134**	2,261,180,512
Lease liabilities – current portion	(6-B)	**3,350,932**	6,755,304
Trade, notes and other payables	(14)	**747,035,669**	584,112,797
Income taxes payable		**55,734,481**	116,575,336
Total current liabilities		**3,106,660,163**	2,983,594,896
TOTAL LIABILITIES		**3,262,866,547**	3,127,627,247
TOTAL EQUITY AND LIABILITIES		**5,637,183,479**	5,337,527,567

Chief financial officer	Board Member
Mohamed Abo Amira	Amr Abdallah Morsy

The accompanying notes from (1) to (35) are an integral part of these consolidated financial statements.

Auditor's Limited Review Attached.

Tenth Of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
For the Three-Month and Six-Month Periods Ended 30 June 2026

	Notes	For the six months ended 30 June 2026 EGP	30 June 2025 EGP	For the three months ended 30 June 2026 EGP	30 June 2025 EGP
Revenues	(22)	**2,120,800,968**	1,828,948,299	**1,054,022,926**	963,331,727
Cost of revenues	(23)	**(1,045,746,407)**	(956,252,780)	**(505,696,539)**	(493,297,339)
GROSS PROFIT		**1,075,054,561**	872,695,519	**548,326,387**	470,034,388
Selling and marketing expenses	(24)	**(424,591,982)**	(305,358,566)	**(222,684,812)**	(173,461,687)
General and administrative expenses	(25)	**(90,209,331)**	(70,566,776)	**(44,306,167)**	(36,904,770)
Other income	(26)	**(32,410)**	4,969,606	**(1,692,305)**	2,498,424
OPERATING PROFIT		**560,220,838**	501,739,783	**279,643,103**	262,166,355
Finance income	(27)	**2,163,633**	16,846,598	**1,408,611**	5,153,468
Finance expenses	(28)	**(251,940,456)**	(266,980,361)	**(119,758,890)**	(134,367,598)
Net foreign exchange gain		**(470,879)**	(4,858,880)	**(6,716,442)**	(1,886,886)
NET FINANCE COST		**(250,247,702)**	(254,992,643)	**(125,066,721)**	(131,101,016)
Impairment of trade and notes receivable – net	(9)	**10,181,999**	(3,991,229)	**10,206,638**	(2,372,921)
Provisions expenses	(13)	**(10,000,000)**	-	**(10,000,000)**	-
Share Based payment expenses		**(31,768,750)**	-	**(15,884,375)**	-
Contribution for health insurance		**(5,994,453)**	(4,798,706)	**(3,246,751)**	(2,537,875)
PROFITS FOR THE PERIOD BEFORE INCOME TAXES		**272,391,932**	237,957,205	**135,651,894**	126,154,543
Income taxes	(29)	**(68,094,654)**	(52,688,896)	**(34,599,047)**	(26,818,856)
PROFITS FOR THE PERIOD		**204,297,278**	185,268,309	**101,052,847**	99,335,687
Attributable to:					
Equity holders of the parent company		**203,087,244**	170,687,821	**100,330,910**	88,444,770
Non-controlling interests		**1,210,034**	14,580,488	**721,937**	10,890,917
PROFITS FOR THE PERIOD		**204,297,278**	185,268,309	**101,052,847**	99,335,687
Basic - Earnings per share	(30)	**0.1015**	0.0853	**0.0501**	0.0442
Diluted - Earnings per share	(30)	**0.1005**	0.0853	**0.0496**	0.0442

Chief financial officer
Mohamed Abo Amira

Board Member
Amr Abdallah Morsy

The accompanying notes from (1) to (35) are an integral part of these consolidated financial statements.

Tenth Of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For The Three-Month and Six-Month Periods Ended 30 June 2026

	For the six months ended		*For the three months ended*	
	30 June 2026	*30 June 2025*	***30 June 2026***	*30 June 2025*
	EGP	*EGP*	***EGP***	*EGP*
PROFITS FOR THE PERIOD	**204,297,278**	185,268,309	**101,052,847**	99,335,687
Other comprehensive income	**-**	-	**-**	-
Other comprehensive income that may be reclassified to profit or loss in subsequent :periods (net of tax)	**-**	-	**-**	-
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	-	-	-	-
Other comprehensive income that will not be reclassified to profit or loss in subsequent :periods (net of tax)	-	-	-	-
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	-	-	-	-
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income, net of tax	**204,297,278**	185,268,309	**101,052,847**	99,335,687
Attributable to:				
Equity holders of the parent company	**203,087,244**	170,687,821	**100,330,910**	88,444,770
Non-controlling interests	**1,210,034**	14,580,488	**721,937**	10,890,917
Total comprehensive income, net of tax	**204,297,278**	185,268,309	**101,052,847**	99,335,687

The accompanying notes from (1) to (35) are an integral part of these consolidated financial statements.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For Six-Month Period Ended 30 June 2026

	Paid up capital	Legal reserve	General Reserve	Treasury shares	Share based Payment	Other reserves	Retained earnings	Total equity of parent company	Non-controlling interest	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Balance as at 1 January 2025	**378,233,733**	**189,116,867**	**327,509,944**	**(26,231,267)**	**13,029,251**	**278,952**	**1,162,330,106**	**2,044,267,586**	**27,376,784**	**2,071,644,370**
Payments to capital increase (Note 15)	1,882,840	-	-	-	-	-	-	1,882,840	-	1,882,840
Retire Treasury shares	(2,367,500)	-	(23,863,767)	26,231,267	-	-	-	-	-	-
Share based Payment reserve	-	-	13,029,251	-	(13,029,251)	-	-	-	-	-
Dividend distributions	-	-	-	-	-	-	(189,600,000)	(189,600,000)	-	(189,600,000)
Total comprehensive income for the period	-	-	-	-	-	-	170,687,821	170,687,821	14,580,488	185,268,309
Balance at 30 June 2025	**377,749,073**	**189,116,867**	**316,675,428**	**-**	**-**	**278,952**	**1,143,417,927**	**2,027,238,247**	**41,957,272**	**2,069,195,519**
Balance as at 1 January 2026	**500,000,000**	**250,000,000**	**255,792,295**	**-**	**12,762,534**	**278,952**	**1,148,943,876**	**2,167,777,657**	**42,122,663**	**2,209,900,320**
Capital increase (Note15)	8,204,334	-	-	-	-	-	-	8,204,334	-	8,204,334
Share based Payment reserve (Note 18)	-	-	-	-	25,415,000	-	-	25,415,000	-	25,415,000
Dividend distributions (Note 30)	-	-	-	-	-	-	(73,500,000)	(73,500,000)	-	(73,500,000)
Total comprehensive income for the period	-	-	-	-	-	-	203,087,244	203,087,244	1,210,034	204,297,278
Balance at 30 June 2026	**508,204,334**	**250,000,000**	**255,792,295**	**-**	**38,177,534**	**278,952**	**1,278,531,120**	**2,330,984,235**	**43,332,697**	**2,374,316,932**

The accompanying notes from (1) to (35) are an integral part of these consolidated financial statements.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
For the Six-Month Period Ended 30 June 2026

	Notes	*30 June 2026* *EGP*	*30 June 2025* *EGP*
OPERATING ACTIVITIES			
Profits for the period before income taxes		272,391,932	237,957,205
Adjustments to reconcile profit before tax to net cash flow:			
Net foreign exchange differences		1,680,184	23,942,575
Depreciation and amortization	(5,6,7)	51,157,474	54,005,597
Share based payment		31,768,750	-
Provision charged		10,000,000	-
Impairment of trade and notes receivable	(9)	(10,181,999)	3,991,229
Impairment of inventory	(8)	11,499,998	6,000,000
Finance income	(27)	-	(15,123,701)
Finance expenses	(28)	244,001,391	266,474,984
Unwinding interests of lease liabilities	(28)	7,939,065	505,377
(Gain) from sale of fixed assets	(5)	(209,357)	(130,766)
Losses from sale of other assets	(12)	2,761,576	-
		622,809,014	577,622,500
Changes in working capital			
Change in inventories		21,036,299	(476,013,952)
Used of inventory provision		(12,151,278)	(5,963,012)
Change in trade and notes receivable		(332,609,127)	(71,469,064)
Change in prepayments and other receivables		(18,931,962)	241,934,886
Change in trade, notes and other payable		149,472,151	(67,766,544)
Cash flows provided from operating activities		429,625,097	198,344,814
Debit interests paid		(236,903,225)	(266,474,984)
Provisions used		-	(2,249,896)
Proceeds from Sales other Assets	(12)	91,077,502	-
Income taxes paid		(116,558,490)	(101,808,330)
NET CASH FLOWS PROVIDED FROM (USED IN) OPERATING ACTIVITIES		167,240,884	(172,188,396)
INVESTING ACTIVITIES			
Payments to acquire fixed assets	(5)	(5,146,538)	(20,623,866)
Payments to acquire assets under construction	(5)	(25,197,725)	(21,157,447)
Payments to acquire intangible assets	(7)	(7,590,515)	(480,214,801)
Matured treasury bills collection		-	237,200,000
Proceeds from sale of fixed assets	(5)	1,086,084	153,651
Investment in term deposits	(11)	220,000	(79,808,397)
NET CASH FLOWS (USED IN) INVESTING ACTIVITIES		(36,628,694)	(364,450,860)
FINANCING ACTIVITIES			
Proceed from capital increase		8,204,334	1,882,840
Credit facilities used	(19)	902,998,639	1,951,642,819
Payment of credit facilities	(19)	(888,611,015)	(1,376,221,813)
Dividends paid during the period		(73,500,000)	(29,266,714)
Lease payments		(9,135,534)	(3,361,207)
NET CASH FLOWS (USED IN) PROVIDED FROM FINANCING ACTIVITIES		(60,043,576)	544,675,925
Net change in cash and cash equivalent during the period		70,568,614	8,036,669
Net foreign exchange difference		(1,680,184)	(23,942,575)
Cash and cash equivalent - beginning of the period		35,958,688	64,276,456
CASH AND CASH EQUIVALENT - END OF THE PERIOD	(11)	104,847,118	48,370,550

The accompanying notes from (1) to (35) are an integral part of these consolidated financial statements.

1- BACKGROUND

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (the "Company" or the "Parent Company") was established under the provisions of Law No. 43 of 1974.

The Company was registered in the commercial registry under No.84008 on 15 January 1986.

The listing of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) on the Egyptian stock exchange was approved in 26 November 2019 according to resolution of listing committee of Egyptian stock exchange.

The registered office is located at plot No. 5 Second Industrial Zone, 6th of October City – Giza– Egypt.

The consolidated financial statements include the financial statements of the Parent Company and its subsidiaries (collectively referred to as the "Group").

The Group is principally engaged in:

- Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use.
- Manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals.
- Importing pharmaceutical reagents and raw materials necessary for serving the Company's purposes without trading.
- Producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others.
- Producing food supplements for human use for others and by others.

The consolidated financial statements for the period ended 30 June 2026 were authorized for issuance in accordance with a resolution of the Board of Directors' dated August 13, 2026.

Below is a brief background about the subsidiaries:

Rameda for Pharmaceuticals Trading Company

A subsidiary with 99.97% shareholding. Its principal activity is importing and exporting pharmaceutical reagents, producing, marketing, selling and storing of pharmaceutical reagents and producing pharmaceutical reagents for human and veterinary and diagnostic use for others

Ramecare Company

A subsidiary with 49% legal ownership. Its principal activity is producing, marketing, selling and storing of pharmaceutical reagents, producing pharmaceutical reagents for human and veterinary and diagnostic use for others.

It was considered a subsidiary since the Parent Company is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over it.

Ramepharma Company

A subsidiary with 49% legal ownership. Its principal activity is producing, marketing, selling and storing of pharmaceutical reagents, producing pharmaceutical reagents for human and veterinary and diagnostic use for others.

It was considered a subsidiary since the Parent Company is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over it.

Glow Company

Tenth of Ramadan for pharmaceutical industries and diagnostic reagents (Rameda) has established Glow company with a 76% ownership, which will specialize in the development and production of cosmetics.

2-SIGNIFICANT ACCOUNTING POLICIES

2-1 BASIS OF PREPARATION CONDENED CONSOLDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements for the six months ended 30 June 2026 have been prepared in accordance with Egyptian Accounting Standard No. (30) 'Interim Financial Reporting'. The consolidated financial statements are prepared under the going concern assumption on a historical cost basis.

The interim condensed consolidated financial statements don't include all data and disclosures required in the annual financial statements and should be read in conjunction with the financial statements for the year ended 31 December 2025. In addition, results for the interim period ended 30 June 2026 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2026, and The Company is not subject to any significant seasonal or cyclical effects.

The interim condensed consolidated financial statements of the Company have been prepared in accordance with the Egyptian accounting standards and the applicable laws and regulations.

The interim condensed consolidated financial statements are prepared and presented in Egyptian pounds, which is the Group's functional currency.

2-2 SIGNIFICANT ACCOUNTING POLICIES

The accounting policies used in the preparation of the interim Condensed Consolidated financial statements are consistent with those used in the preparation of the consolidated financial statements for the period ending on December 31, 2025.

3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES

The preparation of these consolidated financial statements requires management to make judgments and estimates that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities at the reporting date. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the assets or liabilities affected in future periods.

Estimates and their underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised.

The key judgments and estimates that have a significant impact on the consolidated financial statements of the Company are discussed below:

3-1 Judgments

Revenue Recognition for sale of goods

In making their judgment, the management considered the detailed criteria for the recognition of revenue from the sale of goods as set out in "EAS 48 Revenue from contracts with customers'' including the judgement about whether significant risks and rewards have been transferred.

3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES – (CONTINUED)

3-2 Estimates

Impairment of trade and other receivables

An estimate of the collectible amount of trade and other receivables is made when collection of the full amount is no longer probable. For individually significant amounts, this estimate is performed on an individual basis. Amounts which are not individually significant, but are past due, are assessed collectively and a provision is applied according to the length of time past due, based on historical recovery rates.

Provision for sales returns

The Company's management determines the estimates provision for the expected sales returns. This estimate is determined after considering the past experience of sales returns and sales volume and expiry dates of the products sold. The management periodically reviews the estimated provision amount to ensure that provision is adequate to cover the sales return.

Useful lives of fixed assets

The Company's management determines the estimated useful lives of its fixed assets for calculating depreciation. This estimate is determined after considering the expected usage of the asset or physical wear and tear. The management periodically reviews the estimated useful lives and the depreciation method to ensure that the method and the period of depreciation are consistent with the expected pattern of economic benefits from these assets.

Useful lives of intangible assets

The useful lives of intangible assets are assessed as either finite or indefinite. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

The management periodically reviews the estimated useful lives and the amortization method to ensure that the method and the period of amortization are consistent with the expected pattern of economic benefits from these assets- Disclosure no.7.

Taxes

The Company is subject to income taxes in Egypt. Significant judgment is required to determine the total provision for current and deferred taxes. The Company establishes provision, based on reasonable estimates, for possible consequences of audits by the tax authorities in Egypt. The amount of such provision is based on various factors, such as experience of previous tax audits and different interpretations of tax regulations by the Company and the responsible tax authority. Such differences of interpretations may be on a wide variety of issues depending on the conditions prevailing in Egypt.

Deferred tax assets are recognized for unused accumulated tax losses to the extent that it is probable that taxable profits will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Impairment of non-financial assets

The Company assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. The non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. When value in use calculations are undertaken, management estimates the expected future cash flows from the asset or cash-generating unit and chooses a suitable discount rate in order to calculate the present value of those cash flows.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
the Period Ended 30 June 2026

4-SEGMENT INFORMATION

The Group's primary business segment is the production and selling of pharmaceutical products which contributes to 92% of total revenue and balance 8% is contributed by toll manufacturing services (30 June 2025: 93% and 7% receptively). The Group's management monitors the business under two segments, "production and selling of pharmaceutical products" and "manufacturing for others" (Toll manufacturing) for the purpose of making business decisions.

Segment performance is evaluated based on revenue and measured consistently with revenue in the consolidated financial statement.

Accordingly, the Group's revenues during the period ended 30 June 2026 were reported under two segments in the consolidated financial statements.

The Group produces and sells several pharmaceutical products and renders services as follows:

Period	***Services***	***Production and selling of pharmaceutical products***			
	Toll Manufacturing "Domestic"		***Domestic***		
		Export	***Private sales***	***Tenders***	***Total***
	EGP	***EGP***	***EGP***	***EGP***	***EGP***
30 June 2026	**156,858,839**	**148,257,110**	**1,578,209,456**	**237,475,563**	**2,120,800,968**
30 June 2025	148,305,225	107,159,451	1,401,732,833	171,750,790	1,828,948,299

Revenue from the top Five customers presented 67% of total production and selling of pharmaceutical products revenues (30 June 2025:77%).

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
1 January 2026	18,637,425	300,425,231	576,198,512	18,779,803	56,505,776	20,737,158	54,581,769	94,147,562	1,140,013,236
Additions	-	325,295	1,083,887	-	1,041,961	-	2,695,395	25,197,725	30,344,263
Transferred from assets under construction	-	66,627,356	4,173,422	-	8,860,160	-	2,677,930	(82,338,868)	-
Disposals	-	-	(5,286,023)	-	-	(30,920)	(95,761)	-	(5,412,704)
30 June 2026	18,637,425	367,377,882	576,169,798	18,779,803	66,407,897	20,706,238	59,859,333	37,006,419	1,164,944,795
Accumulated depreciation									
As of 1 January 2026,	-	(103,441,678)	(242,628,635)	(14,502,855)	(21,059,039)	(6,451,021)	(31,937,032)	-	(420,020,260)
Depreciation for the period	-	(5,454,637)	(15,383,864)	(585,077)	(2,700,995)	(957,761)	(3,503,552)	-	(28,585,886)
Disposals	-	-	4,458,787	-	-	22,338	54,852	-	4,535,977
30 June 2026	-	(108,896,315)	(253,553,712)	(15,087,932)	(23,760,034)	(7,386,444)	(35,385,732)	-	(444,070,169)
Net book value as of 30 June 2026	18,637,425	258,481,567	322,616,086	3,691,871	42,647,863	13,319,794	24,473,601	37,006,419	720,874,626

- The cost of fixed assets as of 30 June 2026 includes EGP 112,045,756 which represents fully depreciated assets that are still in use.
- The cost of asset under construction as of 30 June 2026 includes impairment by EGP 686,437, (EGP 686,437 as at 31 December 2025).

Depreciation for the period was allocated to the statement of profit or loss as follows:

	30 June 2026
	EGP
Cost of revenue	25,518,637
Selling and marketing expenses	1,150,903
General and administrative expenses	1,916,346
	28,585,886

calculated as follows Gains from sale of fixed assets was:

	30 June 2026
	EGP
Cost of disposed assets	5,412,704
Accumulated depreciation of disposed assets	(4,535,977)
Net book value of disposed assets	876,727
Proceeds from sale of fixed assets	1,086,084
Gains from sale of fixed assets	209,357

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION (CONTINUED)

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
01 January 2025	18,637,425	294,768,429	530,797,844	18,226,904	35,726,446	14,797,847	46,761,370	33,464,541	993,180,806
Additions	-	2,311,386	22,304,280	552,899	17,958,309	5,977,036	4,556,357	102,236,034	155,896,301
Transferred from assets under construction	-	3,345,416	31,191,655	-	2,998,503	-	4,017,439	(41,553,013)	-
Disposals	-	-	(8,095,267)	-	(177,482)	(37,725)	(753,397)	-	(9,063,871)
31 December 2025	18,637,425	300,425,231	576,198,512	18,779,803	56,505,776	20,737,158	54,581,769	94,147,562	1,140,013,236
Accumulated depreciation									
As of 1 January 2025,	-	(93,620,312)	(223,372,292)	(13,311,924)	(17,434,122)	(4,740,068)	(27,543,933)	-	(380,022,651)
Depreciation for the year	-	(9,821,366)	(27,351,129)	(1,190,931)	(3,802,399)	(1,744,499)	(5,102,289)	-	(49,012,613)
Disposals	-	-	8,094,786	-	177,482	33,546	709,190	-	9,015,004
31 December 2025	-	(103,441,678)	(242,628,635)	(14,502,855)	(21,059,039)	(6,451,021)	(31,937,032)	-	(420,020,260)
Net book value as of 31 December 2025	18,637,425	196,983,553	333,569,877	4,276,948	35,446,737	14,286,137	22,644,737	94,147,562	719,992,976

- The cost of fixed assets as of 31 December 2025 includes EGP 114,224,464 which represents fully depreciated assets that are still in use.
- The cost of asset under construction as of 31 December 2025 includes impairment by EGP 686,437. (EGP 686,437 as at 31 December 2024).

Depreciation for the year was allocated to the statement of profit or loss as follows:

	31 December 2025
	EGP
Cost of revenue	44,810,195
Selling and marketing expenses	1,363,532
General and administrative expenses	2,838,912
	49,012,639

Gains from sale of fixed assets was calculated as follows:

	31 December 2025
	EGP
Cost of disposed assets	9,063,871
Accumulated depreciation of disposed assets	(9,015,004)
Net book value of disposed assets	48,867
Proceeds from sale of fixed assets	197,502
Gains from sale of fixed assets	148,635

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

6- LEASES

Right of use assets are scientific rental offices, operating leases, and warehouses

A) Right of use assets

	30 June 2026	*31 December 2025*
	EGP	EGP
Cost at beginning of the period	**100,657,604**	28,026,090
Additions	**1,982,502**	72,631,514
Disposal cost of Right of use assets	**(14,296,983)**	-
Total cost at the end of the period	**88,343,123**	100,657,604
Accumulated amortization at beginning of the period	**(28,501,848)**	(19,668,642)
Amortization for period	**(4,733,975)**	(8,833,206)
Disposal accumulated amortization	**9,902,395**	-
Accumulated amortization at the end of the period	**(23,333,428)**	(28,501,848)
Net book value at the end of the period	**65,009,695**	72,155,756

B) Lease liability

	30 June 2026	*31 December 2025*
	EGP	*EGP*
As at the beginning of the period	**82,216,128**	11,674,259
Addition	**1,982,502**	72,631,514
Disposals	**(6,499,513)**	-
Unwinding interests recognized during the period	**7,939,065**	11,165,109
Disposals adjustment	**2,153,405**	
Lease payments during the period	**(9,135,534)**	(13,254,754)
As at the end of the period	**78,656,053**	82,216,128
Current portion	**3,350,932**	6,755,304
Non-current portion	**75,305,121**	75,460,824
	78,656,053	82,216,128

7- INTANGIBLE ASSETS

	Trademarks (acquired from third parties)*	Registration Rights (Internally developed)**	*IT System*	*Products Under Implementation*	*Total*
		EGP	*EGP*	*EGP*	*EGP*
Cost					
At 1 January 2025	663,693,098	8,843,008	-	9,662,736	682,198,842
Additions	-	2,939,875	15,601,228	1,139,057	19,680,160
Acquisition	575,270,000	-	-	-	575,270,000
At 31 December 2025	1,238,963,098	11,782,883	15,601,228	10,801,793	1,277,149,002
Additions	**-**	**-**	**6,334,143**	**1,256,372**	**7,590,515**
Acquisition	**-**	-	-	-	-
At 30 June 2026	**1,238,963,098**	**11,782,883**	**21,935,371**	**12,058,165**	**1,284,739,517**
Amortization and impairment					
At 1 January 2025	(126,477,949)	(2,935,880)	-	-	(129,413,829)
Amortization	(33,957,110)	(423,885)	-	-	(34,380,995)
Impairment	-	(2,556,770)	-	-	(2,556,770)
At 31 December 2025	(160,435,059)	(5,916,535)	-	-	(166,351,594)
Amortization	(17,649,494)	(188,119)	-	-	(17,837,613)
Impairment		-	-	-	-
At 30 June 2026	**(178,084,553)**	**(6,104,654)**	-	-	**(184,189,207)**
Netbook value					
At 1 January 2025	537,215,149	5,907,128	-	9,662,736	552,785,013
At 31 December 2025	1,078,528,039	5,866,348	15,601,228	10,801,793	1,110,797,408
At 30 June 2026	**1,060,878,545**	**5,678,229**	**21,935,371**	**12,058,165**	**1,100,550,310**

* The balance of Trademarks (acquired from third parties) represents registration rights and trademarks relating to certain pharmaceutical products that were purchased from external parties and are legally registered. These assets are initially recognized at cost and subsequently measured using the historical cost model. These trademarks have finite useful lives and are amortized using the straight-line method over their estimated useful lives.

** The balance of intangible assets also includes registration rights for other pharmaceutical products registered by the Company with Egyptian Drug Authority (EDA). These registration rights are amortized using the straight-line method over their estimated useful lives.

- During the previous financial year ended 31 December 2025, management, as part of its periodic review of accounting estimates, reassessed the estimated useful life of certain pharmaceutical product trademarks recognized within intangible assets in accordance with Egyptian Accounting Standard (EAS) No. 23 – Intangible Assets. As a result of this review, the estimated useful life of certain trademarks was revised from the previously estimated useful life of 20 years to a revised useful life ranging from 35 to 40 years.
- This reassessment was performed in accordance with the requirements of EAS No. 23, which requires that the useful life of an intangible asset reflect the period over which future economic benefits are expected to be derived from the asset. The assessment took into consideration historical experience with similar products containing the same active ingredient, market demand, the product life-cycle stage, and industry practices relating to comparable pharmaceutical products with the same active ingredient.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

7- INTANGIBLE ASSETS (CONT)

- Based on an updated analysis that considered the product's expected economic life, continued medical significance, historical and projected sales performance, and the useful lives applied to comparable pharmaceutical trademarks in the market, management concluded that the previously applied useful life no longer appropriately reflected the pattern in which the future economic benefits associated with the trademarks are expected to be consumed.

- This revision has been accounted for as a change in accounting estimate in accordance with Egyptian Accounting Standard (EAS) No. 5 – Accounting Policies, Changes in Accounting Estimates and Errors, and has been applied prospectively from the date of reassessment.

Quantitative Impact of the Change

- As a result of revising the estimated useful life to 35-40 years, the amortization expense recognized during the current period decreased by EGP 12,716,447. Comparative figures for the six-month period ended 30 June 2025 have not been restated or adjusted.
- Management will continue to review the estimated useful life of the trademarks at each reporting date and will revise the estimate whenever events or changes in circumstances indicate that the expected useful life has changed, in accordance with the requirements of EAS No. 23 – Intangible Assets.

8- INVENTORIES

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Raw materials	**385,929,541**	462,043,750
Packing and packaging materials	**130,543,566**	154,966,880
Spare parts	**68,353,868**	62,253,466
Finished goods	**214,186,012**	291,842,518
Work in progress	**19,416,896**	20,667,139
Goods in transit	**184,572,028**	32,785,728
Inventory with others	**17,168,794**	16,647,523
	1,020,170,705	1,041,207,004
Write down in inventories	**(9,090,633)**	(9,741,913)
	1,011,080,072	1,031,465,091

The movement in the write down in value of inventories as follows:

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Beginning balance of the period	**(9,741,913)**	(16,269,147)
Charge during the period *	**(11,499,998)**	(18,495,242)
Used during the period	**12,151,278**	25,022,476
Ending balance of the period	**(9,090,633)**	(9,741,913)

*The write down in value of inventories during the period was included in the cost of sales.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

9- TRADE AND NOTES RECEIVABLES

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Trade receivable	**1,037,105,464**	1,104,263,563
Trade receivable – toll manufacturing	**55,715,788**	53,596,958
Notes receivable	**1,486,026,305**	1,088,377,909
	2,578,847,557	2,246,238,430
Impairment in value of trade and notes receivables	**(120,766,511)**	(130,948,510)
	2,458,081,046	2,115,289,920

- Notes receivable amounting to EGP **839** M are mortgage as a guarantee for the credit facilities (Note **19**).

The movement of the impairment in value of trade and notes receivable as follows:

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Beginning balance of the period	**(130,948,510)**	(26,149,830)
Charged during the period	**10,181,999**	(104,798,680)
Ending balance of the period	**(120,766,511)**	(130,948,510)

The aging analysis of gross trade and notes receivable before impairment is as follows:

			Past due but not impaired				*Impaired*
	Total	***Neither past due nor impaired***	***Less than 180 days***	***From 181 to 270 days***	***From 271 to 365 days***	***More than 365 days***	
	EGP	**EGP**	**EGP**	**EGP**	**EGP**	**EGP**	**EGP**
30 June 2026	**2,578,847,557**	**2,436,000,637**	**21,476,009**	**-**	**-**	**604,400**	**120,766,511**
31 December 2025	2,246,238,430	2,093,945,461	16,126,843	4,227,335	990,281	-	130,948,510

The balances of trade receivables and notes receivable include an amount of EGP 99,378,332 related to a single customer, in addition to related parties of the same customer. The company has been negotiating with the customer to settle the outstanding debt, given that the customer has been facing delays in payment and showing negative indicators regarding its financial position, as well as defaults with other companies. In this context, real estate assets were acquired in previous years to settle part of the outstanding debt, and these assets have been disclosed in Note (12).
The company continues to negotiate with the customer to collect the remaining outstanding amounts.
As of 31 December 2025, the customer's balance before recognizing allowances amounted to EGP 99,378,332.
The company assessed the impairment of this balance on an individual basis, and as a result, an impairment loss of EGP 99,378,332 was recognized during the year ended 31 December 2025. This brought the total allowance recorded for this customer to the same amount, which equals the entire receivable balance, resulting in a net customer balance of zero as of 31 December 2025 In June 2026, an amount of EGP 10 million was settled against the outstanding liability, reducing the balance to **EGP 89,378,332**. Accordingly, the related provision was reduced by the same amount as the settlement.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

10- PREPAYMENTS AND OTHER RECEIVABLES

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Prepaid expenses	**15,441,838**	10,491,247
Advances to suppliers	**81,159,228**	48,084,794
Tax authority	**20,944,662**	52,457,929
Payment under fixed assets acquisition	**17,980,156**	29,422,762
Deposits with others	**1,578,206**	2,120,940
Employees' imprests and advances	**2,096,759**	3,263,586
Prepayment to customs-authority	**4,964,264**	1,943,711
Other receivables	**32,549,999**	9,998,181
	176,715,112	157,783,150

11- CASH ON HAND AND AT BANKS

	30 June 2026	*31 December 2025*
	EGP	*EGP*
a) Egyptian Pounds		
Cash on hand	**99,050**	18,296
Current accounts	**48,931,545**	27,590,766
Checks under collection	**48,597,882**	5,540,065
Term deposits	**-**	220,000
	97,628,477	33,369,127
b) Foreign currencies		
Cash on hand	**1,138,312**	584,797
Current accounts	**6,080,329**	2,224,764
	7,218,641	2,809,561
	104,847,118	36,178,688

Cash on hand and at banks balances are denominated in the following currencies:

	30 June 2026	*31 December 2025*
	EGP	EGP
Egyptian pound (EGP)	**97,628,477**	33,369,127
US dollar (USD)	**7,109,949**	2,792,211
Euro (EUR)	**108,692**	17,350
	104,847,118	36,178,688

For the purpose of cash flow statements cash and cash equivalents consist of following.

	30 June 2026	*30 June 2025*
	EGP	*EGP*
Cash in hand	**1,237,361**	726,943
Checks under collection	**48,597,882**	21,132,036
Current accounts	**55,011,875**	26,511,571
	104,847,118	48,370,550

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

12- OTHER ASSETS

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Beg of the year	**93,839,078**	93,839,078
Proceeds from the sale of real estate units	**(91,077,502)**	-
Loss on Disposal of Assets	**(2,761,576)**	-
	-	93,839,078

Other assets represent the acquisition cost of real estate units (residential units) that were assigned to Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) under a preliminary sale agreement dated 28 August 2024. The units were transferred by one of the Company's customers in settlement of an outstanding receivable balance. The Company determined the acquisition value based on the market prices of comparable real estate units in the Egyptian real estate market. During the period, the Company sold all of these units.

13- PROVISIONS

	Balance as at 1 January 2026 EGP	***Charged during the period EGP***	***Used during the period EGP***	***Balance as at 30 June 2026 EGP***
Provision for expected claims	**4,238,200**	**10,000,000**	**-**	**14,238,200**
Provision for sales returns*	**10,732,747**	**-**	**-**	**10,732,747**
	14,970,947	**10,000,000**	**-**	**24,970,947**

	Balance as at 1 January 2025 EGP	***Charged during the year EGP***	***Used during the year EGP***	***Balance as at 31 December EGP***
Provision for expected claims	6,308,097	-	(2,069,897)	4,238,200
Provision for sales returns*	10,912,747	-	(180,000)	10,732,747
	17,220,844	-	(2,249,897)	14,970,947

*Provision for sales returns is deducted from sales disclosed (Note 22).

14- TRADE, NOTES AND OTHER PAYABLES

	30 June 2026 EGP	*31 December 2025 EGP*
Trade payables	**440,700,304**	335,190,233
Notes payables	**59,684,350**	65,156,850
Accrued expenses	**146,140,726**	134,890,738
Tax authority (other than income tax)	**24,763,643**	19,865,164
Advances from customer	**62,923,722**	18,546,086
Dividend Payables	**991,246**	687,499
Other payables	**11,831,678**	9,776,227
	747,035,669	584,112,797

Trade payables, notes and other payables are non-interest bearing.

15- CAPITAL

- The Company's authorized capital amounted to one billion Egyptian pounds, while the issued and paid-up capital amounted to EGP 508,204,334 distributed over 2,032,817,336shares with a nominal value of EGP 0.25 per share.
- Pursuant to the resolution of the Extraordinary General Assembly dated 14 October 2020, the Board of Directors' meeting held on 4 January 2023 resolved to increase the Company's issued and paid-up capital from EGP 250,000,000 to EGP 252,112,680, an increase of EGP 2,112,680 distributed over 8,450,720 shares, funded from payments made by beneficiaries of the scheme, to be allocated entirely to the Company's employee incentive and reward scheme. Accordingly, the Company's capital issued after the increase became EGP 252,112,680 distributed over 1,008,450,720 shares with a nominal value of EGP 0.25 per share. The amount paid under capital increase reached EGP 252,112,680 as at 31 December 2023.
- An amount of EGP 2,112,680 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 9 January 2023, the Company's issued and paid-up capital was increased from EGP 250,000,000 to EGP 252,112,680, an increase of EGP 2,112,680 distributed over 8,450,720 shares.
- The Company's authorized capital amounts to Egyptian Pounds 1 billion, while the issued and fully paid capital amounts to Egyptian Pounds 508,204,334, divided into 2,032,817,336 ordinary shares with a nominal value of Egyptian Pounds 0.25 per share.
- The Company's authorized capital amounted to one billion Egyptian pounds, while the issued and paid-up capital amounted to EGP 500,000,000 distributed over 2,000,000,000 shares with a nominal value of EGP 0.25 per share.
- Pursuant to the resolution of the Extraordinary General Assembly dated 14 October 2020, the Board of Directors' meeting held on 4 January 2023 resolved to increase the Company's issued and paid-up capital from EGP 250,000,000 to EGP 252,112,680, an increase of EGP 2,112,680 distributed over 8,450,720 shares, funded from payments made by beneficiaries of the scheme, to be allocated entirely to the Company's employee incentive and reward scheme. Accordingly, the Company's capital issued after the increase became EGP 252,112,680 distributed over 1,008,450,720 shares with a nominal value of EGP 0.25 per share. The amount paid under capital increase reached EGP 252,112,680 as at 31 December 2023.
- An amount of EGP 2,112,680 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 9 January 2023, the Company's issued and paid-up capital was increased from EGP 250,000,000 to EGP 252,112,680, an increase of EGP 2,112,680 distributed over 8,450,720 shares.
- The Extraordinary General Assembly meeting held on 16 August 2023 resolved to increase the issued and paid-up capital by EGP 127,887,320 through the distribution of bonus shares at a ratio of 0.52253 bonus share for each original share, based on 978,980,720 shares after excluding treasury shares, with fractions rounded up in favor of small shareholders from smallest to largest, funded from the Company's distributable net profits (current year profits + retained earnings) for the financial year ended 31 December 2022. As a result, the Company's issued capital after the increase became EGP 380,000,000 distributed over 1,520,000,000 shares with a nominal value of EGP 0.25 per share. This was registered in the Commercial Register on 20 September 2023.
- The Extraordinary General Assembly meeting held on 16 August 2023 also resolved to reduce the issued and paid-up capital from EGP 380,000,000 to EGP 375,000,000, a reduction of EGP 5,000,000, through the cancellation of treasury shares listed among shares held by public and private offering shareholders, totaling 20,000,000 shares at a nominal value of EGP 0.25 per share.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

15- CAPITAL - (CONTINUED)

- Pursuant to the resolution of the Extraordinary General Assembly dated 14 October 2020, the Board of Directors' meeting held on 27 May 2024 resolved to increase the Company's issued and paid-up capital from EGP 375,000,000 to EGP 378,233,733, an increase of EGP 3,233,733 distributed over 12,934,932 shares, funded from payments made by beneficiaries of the scheme, to be allocated entirely to the Company's employee incentive and reward scheme. Accordingly, the Company's issued capital after the increase became EGP 378,233,733 distributed over 1,512,934,932 shares with a nominal value of EGP 0.25 per share.
- An amount of EGP 3,233,733 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 2 June 2024, the Company's issued and paid-up capital was increased from EGP 375,000,000 to EGP 378,233,733, an increase of EGP 3,233,733 distributed over 12,934,932 shares.
- On 6 January 2025, 9,470,000 treasury shares were cancelled at a nominal value of EGP 0.25 per share, with a total value of EGP 2,367,500, resulting in a corresponding reduction in capital by the same amount.
- An amount of EGP 1,882,840 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 12 March 2025, the Company's issued and paid-up capital was increased from EGP 375,886,232 to EGP 377,749,073, an increase of EGP 1,882,840 distributed over 7,531,360 shares. The Extraordinary General Assembly meeting held on 13 May 2025 resolved to increase the issued and paid-up capital from EGP 375,886,232 to EGP 377,749,073, an increase of EGP 1,882,840 through the issuance of 7,531,360 shares with a nominal value of EGP 0.25 per share, allocated entirely to the incentive and reward scheme of Tenth of Ramadan for Pharmaceutical Industries and
- Diagnostic Reagents (Rameda) (S.A.E), funded in cash from payments made by scheme beneficiaries in accordance with the applicable scheme tranche.
- Pursuant to the Board of Directors' meeting held on 9 March 2025 approving the profit distribution plan for the financial year ended 31 December 2024, which included the distribution of bonus shares amounting to EGP 122,250,927, the Ordinary General Assembly meeting held on 29 April 2025 approved the distribution of bonus shares to shareholders amounting to EGP 122,250,927, funded entirely from the Company's distributable net profits for the year in accordance with the financial statements for the year ended 31 December 2024. The increase of EGP 122,250,927 is distributed over 489,003,708 original shares at a ratio of 0.3236 bonus share per share, with a nominal value of EGP 0.25 per share. The capital increase through bonus shares was registered in the Commercial Register on 2 November 2025.
- The Extraordinary General Assembly meeting held on 19 May 2026 approved an increase in the issued and paid-up share capital, within the limits of the authorized capital, by EGP 8,204,334, increasing the share capital from EGP 500,000,000 to EGP 508,204,334. The increase was effected through the issuance of new shares allocated entirely to the Company's Employee Stock Ownership and Incentive Scheme (ESOP) and financed in cash from the payments made by the beneficiaries of the second tranche of the scheme, in accordance with the resolution of the Extraordinary General Assembly held on 14 October 2020.

  The increase in the issued and paid-up share capital was registered with the Commercial Register on 16 June 2026, resulting in the issued and paid-up share capital becoming EGP 508,204,334, divided into 2,032,817,336 shares, with a nominal value of EGP 0.25 (twenty-five piasters) per share.

15- CAPITAL - (CONTINUED)

The following illustrate the structure for shareholders as at 30 June 2026:

	%	*No. of shares*	*Amount EGP*
Main shareholder's shares	**52.02%**	**1,057,379,965**	**264,344,991**
Other listed free shares in Stock Exchange Market	**47.98%**	**975,437,371**	**243,859,343**
	100%	**2,032,817,336**	**508,204,334**

The following illustrate the structure for shareholders as at 31 December 2025:

	%	*No. of shares*	*Amount EGP*
Main shareholder's shares	40.67%	813,435,146	203,350,000
Other listed free shares in Stock Exchange Market	59.33%	1,186,564,854	296,650,000
	100%	**2,000,000,000**	**500,000,000**

16- GENERAL RESERVE

The balance of the general reserve represents the net book value of the capital increase shares issued during 2019, amounting to EGP 486,965,000 for the issuance of 125,000,000 shares, after deducting issuance costs of EGP 64,285,000.

Pursuant to Article (94) of the Executive Regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of EGP 89,443,310 was transferred to the legal reserve to reach 50% of the issued and paid-up capital.

The capital was reduced through the cancellation of 20,000,000 shares amounting to EGP 5,000,000 at a nominal value of EGP 0.25 per share, and an amount of EGP 34,694,932 from the general reserve balance, representing the difference between the market value of the purchased shares and their nominal value.

A balance of EGP 14,473,267 was transferred from the incentive and reward provisions, representing the fair value of shares granted to a group of employees, using the share price announced on the Egyptian Stock Exchange on the grant date, amounting to EGP 2.01 per share.

Pursuant to Article (94) of the Executive Regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of EGP 64,116,867 was transferred to the legal reserve to reach 50% of the issued and paid-up capital.

A balance of EGP 13,927,085 was transferred from the incentive and reward provisions, representing the fair value of shares granted to a group of employees, using the share price announced on the Egyptian Stock Exchange on the grant date, amounting to EGP 1.31 per share.

The capital was reduced through the cancellation of 9,470,000 shares amounting to EGP 2,367,500 at a nominal value of EGP 0.25 per share, and an amount of EGP 23,863,767 from the general reserve balance, representing the difference between the market value of the purchased shares and their nominal value.

16- GENERAL RESERVE - (CONTINUED)

On 12 May 2024, the Company activated its incentive and reward program, through which a number of employees, managers, and executive board members were granted stock options for a total of 7,531,359 shares at a nominal value of EGP 0.25 per share, subject to continued service for the required period until the exercise date, in accordance with the approval of the Financial Regulatory Authority issued on 11 June 2025.

The transferred balance represents the fair value of shares granted to a group of employees amounting to EGP 13,029,251, using the share price announced on the Egyptian Stock Exchange on the grant date, amounting to EGP 1.98 per share.

Pursuant to Article (94) of the Executive Regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of EGP 60,883,133 was transferred to the legal reserve to reach 50% of the issued and paid-up capital.

	30 June 2026	*31 December 2025*
	EGP	*EGP*
Beginning Balance	***255,792,295***	*327,509,944*
Transfer to legal Reserve	-	*(60,883,133)*
Disposing treasury shares	-	(23,863,767)
Transfer from share based payment	-	13,029,251
	255,792,295	255,792,295

17- TREASURY SHARES

The Board of Directors' meetings held on February 23, 2022, May 31, 2022, and September 4,2022, decided to repurchase treasury shares not exceeding 10% of the Company's total issued share capital through the open market.

Pursuant to the Board of Directors' resolution issued on February 23, 2022, and on May 31,2022, and on September 4, 2022, the company purchased 29,470,000 shares from the stock exchange and retained them in the treasury for a total consideration of EGP 65,926,198. The consideration paid was recognized as a revaluation in the statement of shareholders' equity.

During 2022, the company purchased 20 million shares for EGP 39,694,932. According to Article 48 of Law No. 159 of 1981, the company must dispose of treasury shares to third parties within one year of acquiring them, otherwise it will be obligated to reduce its capital by the nominal value of those shares, following the established procedures. The company has currently reduced its capital by the nominal value, totaling EGP 5,000,000.

The Board of Directors meeting held on May 13, 2024, decided to approve the capital reduction procedures by disposing of the company's treasury shares, which number 9,470,000 shares, for an amount of EGP 2,365,500.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

17- TREASURY SHARES – (CONTINUED)

The Extraordinary General Assembly meeting held on Dec 10, 2024, approved a capital reduction by canceling the company's treasury shares, amounting to 9,470,000 shares, for an amount of EGP 2,365,500, after completing all necessary procedures for capital reduction through the cancellation of the company's treasury shares. The decision was made by the General Authority for Investment and Free Zones on January 8, 2025.

		30 June 2026		*31 December 2025*	
		Shares	*Amount EGP*	*Shares*	*Amount EGP*
Beginning Balance		-	-	*9,470,000*	*26,231,267*
Purchases During the period		-	-	-	-
Sold during the period		-	-	-	-
Disposed during the period	Reduce capital	-	-	(9,470,000)	**(2,367,500)**
	Transfer to general reserve	-			**(23,863,767)**
		-	-	-	-

18- SHARE BASED PAYMENT RESERVE

The company has approved the reward and incentive program for employees, managers and executive board members under the program the company grant the beneficiaries Ordinary share options at the nominal value in accordance with the approval of the Extraordinary General Assembly on October 14, 2020, and this program allows employees, managers and executive board members who benefit from the incentive and reward system to own part of the company's shares in accordance to listing and Trading Rules of Egyptian Stock Exchange under the provisions of Law 159 for year 1981 and its executive regulations and under the provision of law 95 for year 1992 and its executive regulations.

On 12 May 2024 the company activated the reward and incentive program. Giving number of employees, managers and executive board members share options for a total of 7,531,359 shares at the nominal value (0.25 EGP per share) on condition of staying in service for the required period till the exercise date which agreed with Financial regulatory authority approval on 11 June 2025.

The fair value of the granted shares for numbers of employees were 13,029,251 Egyptian Pound using the price of the share announced in the Egyptian Stock Exchange on the grant date (1.98 EGP for share) before the deduction of the nominal value of shares that would be paid by the beneficiaries in cash.

During the year 2025, the Company established an incentive and reward provision in accordance with the scheme tranche determined by the Incentive and Reward Committee and to be approved by the Board of Directors. This provision relates to certain employees, managers, and executive board members, and includes a promise to sell a total of 15,567,34 shares at par value (EGP 0.25 per share), conditional upon completing the required service period up to the exercise date and achieving the required performance evaluations.

A maximum number of shares was determined for each employee in accordance with the share sale agreements, with the right to exercise the purchase being limited to a maximum period of one month from the exercise date. The fair value of the total shares granted to certain employees amounted to EGP 25,470,034 as of 30 June 2026, based on the share price on the Egyptian Stock Exchange at the grant date (EGP 1.55), before deducting the nominal value of the share to be paid in cash by the beneficiaries under the scheme.

18- SHARE BASED PAYMENT RESERVE – (CONTINUED)

On 30 March 2026, the Board of Directors unanimously approved submitting a proposal to the Extraordinary General Assembly to increase the issued share capital of the company, within the limits of the authorized capital, from EGP 500,000,000 to EGP 508,204,334, representing an increase of EGP 8,204,334, through the issuance of 32,817,336 additional shares.

This increase will be effected through the issuance of new shares fully allocated to the Employees' Reward and Incentive Scheme of Tenth of Ramadan Pharmaceutical Industries and Diagnostic Reagents Company (Rameda S.A.E.), to be funded in cash by the beneficiaries of the scheme in accordance with the scheme's tranches.

During the period, the total fair value of the granted shares amounted to EGP 12,707,500 for 5,750,000 shares allocated to certain employees, based on the share price on the Egyptian Exchange at the grant date (EGP 2.46 per share), before deducting the nominal value of the shares, which will be borne by the beneficiaries in cash.

On 19 May 2026, the Extraordinary General Assembly approved the increase in the Company's issued share capital, within the limits of the authorized capital, from EGP 500,000,000 to EGP 508,204,334, representing an increase of EGP 8,204,334, through the issuance of 32,817,336 ordinary shares with a nominal value of EGP 0.25 per share. The newly issued shares were allocated in full to the Company's Employee Stock Ownership and Incentive Plan and are to be funded in cash by the beneficiaries in accordance with the applicable tranche of the plan. During the period, 11,500,000ordinary shares were granted to certain employees with an aggregate fair value of EGP 25,415,000, determined using the quoted market price of EGP 2.46 per share on the grant date, before deducting the nominal value of the shares payable in cash by the beneficiaries.

Movement of equity instruments during the period as follows:

	30 June 2026		*31 December 2025*	
	Amount EGP	**Shares No.**	Amount EGP	Shares No.
Balance at 1 January 2026	**12,762,534**	**9,817,334**	13,029,251	7,531,359
Granted during the period / year	**25,415,000**	**11,500,000**	12,762,534	9,817,334
Exercised during the period / year	**-**	-	(13,029,251)	(7,531,359)
Total shares at the end of year	**38,177,534**	**21,317,334**	12,762,534	9,817,334

19- CREDIT FACILITIES

The movement of the credit facilities during the period is as follows:

	30 June 2026 EGP	*31 December 2025 EGP*
Beginning balance of the year	**2,260,551,940**	1,505,994,906
Used during the period	**899,410,871**	3,435,247,434
Payment during the period	**(888,611,015)**	(2,680,690,400)
Ending balance of the period	**2,271,351,796**	2,260,551,940

	30 June 2026 EGP	*31 December 2025 EGP*
Credit facilities maturing within 12 months	**2,271,351,796**	2,260,551,940
Bank credit balances	**4,216,338**	628,572
	2,275,568,134	2,261,180,512

- The interest rate on the Credit facilities ranges from 19.50% to 22.42% as of 30 June 2026 (31 December 2025: Range from 15% to 25.27%).

Credit Facilities	Facility amount EGP	***30 June 2026 EGP***	*31 December 2025 EGP*
CIB	700,000,000	**518,816,665**	597,934,320
FAB	200,000,000	**175,755,220**	115,926,825
Arab Bank	250,000,000	**229,337,087**	177,500,100
ABK	120,000,000	**69,949,065**	94,256,469
ADIB	400,000,000	**342,796,931**	400,165,403
Alex Bank	300,000,000	**170,936,737**	147,478,063
AUB	250,000,000	**243,548,280**	206,386,406
ENBD	100,000,000	**-**	6,498,431
AWB	160,000,000	**157,451,894**	158,892,950
Banque Misr	300,000,000	**296,805,958**	204,003,066
NBK	300,000,000	**65,953,959**	151,509,907
Total credit facilities		**2,271,351,796**	2,260,551,940

Some of the above facilities are guaranteed by notes receivable (Note 9).

20- CAPTIAL COMMITMENTS

On June 30, 2026, the Company's contractual obligations for assets under construction, machinery and equipment of production activity, which were not included in the financial statements, amounted to EGP 61,466,873.52compared to (EGP 58,753,983 on December 31, 2025).

On 5 December 2024, the Company signed a contract with SAP for the implementation of the SAP accounting system, with a total contract value of USD 1,517,885 payable in equal installments from March 2025 through March 2032, in addition to USD 280,000 for system implementation and operation services. The Company is currently in the preparation phase, and the system implementation is expected to commence in Jan 2027.

21- CONTINGENT LIABILITIES

	30 June 2026 ***EGP***	*31 December 2025* *EGP*
Undraw downs Letter of Credits *	**11,046,926**	6,015,569
Non-Accrued Leases **	**4,377,335**	13,659,643
Refundable lease insurance **	**13,152,000**	13,152,000
	28,576,261	32,827,212

* The Company has opened letters of credit in favor of suppliers for the purpose of importing raw materials and production inputs. As of the reporting date, no drawdowns have been made against these letters of credit.
** The Company issued checks upon the signing of a lease agreement, representing amounts paid in advance for future lease periods or refundable deposits recoverable upon termination of the contractual relationship.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

22- REVENUES

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Sale of goods (net)	**1,963,942,129**	1,680,643,074	**976,692,016**	869,914,342
Toll manufacturing services revenue	**156,858,839**	148,305,225	**77,330,910**	93,417,385
	2,120,800,968	1,828,948,299	**1,054,022,926**	963,331,727

23- COST OF REVENUES

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Salaries and incentives	**136,611,399**	120,958,428	**71,453,178**	63,723,090
Social insurance and other benefit	**33,949,653**	32,035,109	**17,532,992**	16,926,061
Raw materials	**659,539,532**	571,025,631	**306,703,779**	296,168,443
Spare parts and materials	**24,459,495**	45,852,839	**14,743,419**	19,628,778
Government fees and medical stamps	**10,822,985**	13,366,593	**4,867,091**	6,180,083
Other operating expenses	**46,682,155**	36,330,153	**20,590,236**	21,048,539
Energy expenses	**43,883,057**	38,636,786	**25,949,181**	21,393,902
Depreciation and amortization (Note 5,6 &7)	**43,356,250**	50,078,250	**22,753,024**	28,808,071
Rent	**19,235,355**	14,375,435	**7,852,575**	4,308,495
Maintenance	**27,206,526**	33,593,556	**13,251,064**	15,111,877
	1,045,746,407	956,252,780	**505,696,539**	493,297,339

24- SELLING & MARKETING EXPENSES

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Salaries and incentives	**170,652,966**	124,756,604	**89,658,876**	68,735,659
Social insurance and other benefit	**18,114,147**	15,108,376	**8,912,553**	7,966,441
Depreciation (Note 5,6)	**5,410,018**	2,670,932	**2,933,987**	1,335,323
Rent	**12,500**	37,500	**-**	-
Advertising and marketing	**230,402,351**	162,785,154	**121,179,396**	95,424,263
	424,591,982	305,358,566	**222,684,812**	173,461,687

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

25- GENERAL & ADMINISTRATIVE EXPENSES

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Salaries and incentives	**54,883,565**	52,028,627	**25,016,615**	28,098,349
Social insurance and other benefit	**3,675,050**	3,353,496	**1,769,941**	1,607,550
Professional fees	**6,185,918**	2,924,201	**3,266,527**	276,410
Maintenance	**955,615**	1,376,645	**451,624**	698,789
Depreciation (Note 5,6)	**2,391,206**	1,232,406	**1,269,000**	595,187
Others	**22,117,977**	9,651,401	**12,532,460**	5,628,485
	90,209,331	70,566,776	**44,306,167**	36,904,770

26- OTHER INCOME

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Gain from sale of fixed assets (Note 5)	**209,357**	130,766	**(869,876)**	37,136
(Loss) gain Other Assets (note 12)	**(2,761,576)**		**(2,761,576)**	
Other income	**2,519,809**	4,838,840	**1,939,147**	2,461,288
	(32,410)	4,969,606	**(1,692,305)**	2,498,424

27- FINANCE INCOME

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Interest from treasury bills	**-**	15,123,701	**-**	3,944,678
Interest from time deposits	**2,163,633**	1,722,897	**1,408,611**	1,208,790
	2,163,633	16,846,598	**1,408,611**	5,153,468

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

28- FINANCE EXPENSES

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Debit interests	**239,996,247**	263,196,663	**112,833,431**	132,709,697
Unwinding interests of lease liabilities (Note 6)	**7,939,065**	505,377	**5,065,780**	234,303
Bank Charges	**4,005,144**	3,278,321	**1,859,679**	1,423,598
	251,940,456	266,980,361	**119,758,890**	134,367,598

29- INCOME TAXES

	Six Months ended		Three months ended	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Current income tax	**(55,764,918)**	(63,759,566)	**(31,331,203)**	(29,220,155)
Deferred income tax	**(12,329,736)**	11,070,670	**(3,267,844)**	2,401,299
Income tax expense	**(68,094,654)**	(52,688,896)	**(34,599,047)**	(26,818,856)

DEFERED INCOME TAXES

	Statement of financial position		*Statement of profit or loss*	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Fixed assets and intangible assets	**(123,850,541)**	(111,967,013)	**(11,883,528)**	12,276,427
Provisions	**57,000,338**	2,466,240	**54,534,098**	(222,410)
Impairment of trade and notes receivables	**(27,219,421)**	29,441,966	**(56,661,387)**	869,179
Write down in value of inventory	**2,045,392**	2,191,930	**(146,538)**	8,322
Share based payment reserve	**10,737,431**	3,589,463	**7,147,968**	(3,664,477)
Unrealized foreign exchange differences	**385,538**	5,705,887	**(5,320,349)**	-
Others	**-**	-	**-**	1,803,629
Net deferred income taxes	**(80,901,263)**	(68,571,527)	**(12,329,736)**	11,070,670

RECONCILIATION OF THE EFFECTIVE INCOME TAX RATE

	Tax Rate	***30 June 2026 EGP***	*Tax Rate*	*30 June 2025 EGP*
Profits before income taxes		**272,391,932**		237,957,205
Income tax based on tax rate	**22.50%**	**61,288,185**	22.50%	53,540,371
Non-deductible expenses		**6,806,469**		(851,475)
Effective Tax Rate	**25.00%**	**68,094,654**	22.73%	52,688,896

30- EARNINGS PER SHARE

Basic and diluted earnings per share were calculated by dividing the profits for the year available for distribution to the Parent Company by the weighted average number of shares outstanding during the year as follows:

	Six Months ended		**Three months ended**	
	30-Jun-26	*30-Jun-25*	***30-Jun-26***	*30-Jun-25*
	EGP	*EGP*	***EGP***	*EGP*
Net profit attributable to shareholders of the parent company	**203,087,244**	170,687,821	**100,330,910**	88,444,770
Weighted average number of outstanding shares after the effect of treasury share purchases during the period	**2,001,367,389**	2,000,000,000	**2,001,367,389**	2,000,000,000
Effect of dilutive shares:				
Share purchase rights for employees and executive directors	**20,098,163**	-	**20,098,163**	-
Weighted average number of shares after the effect of reduction during the period	**2,021,465,552**	2,000,000,000	**2,021,465,552**	2,000,000,000
Basic earnings per share	**0.1015**	0.0853	**0.0501**	0.0442
Diluted earnings per share	**0.1005**	0.0853	**0.0496**	0.0442

- As detailed in Note (15) “Issued and Paid-up Capital,” the shareholders of the Company, in accordance with the resolution of the Ordinary General Assembly held on 29 April 2025, approved the distribution of bonus shares at a rate of 0.3236 bonus shares for each original share. Accordingly, the weighted average number of outstanding shares in the comparative figures has been adjusted in accordance with Egyptian Accounting Standard No. (22) “Earnings per Share.”

- On 30 March 2026, the Board of Directors proposed a profit distribution amounting to EGP 73,500,000, which was approved by the Ordinary General Assembly on 4 May 2026.

31- TAX POSITION

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

The Company is committed to filing its corporate income tax returns within the statutory deadlines in accordance with the provisions of Article 83 of the applicable Income Tax Law.

The Company's books and records have been examined by the Egyptian Tax Authority from the commencement of operations through the fiscal year **2019**, and the related tax assessments have been finalized and settled.

The Company is currently preparing for the tax examination covering the fiscal years **2020 to 2022**.

The Company not yet received notification for tax examination for coming years.

2. Payroll Tax

The payroll tax file has been examined from the commencement of operations through the fiscal year **2022**, and the related tax assessments have been finalized and settled.

The Company is currently preparing the fiscal year **2023** for tax examination.

The Company not yet received notification for tax examination for coming years.

3. Stamp Duty Tax

The Company's books and records have been examined for stamp duty tax purposes through the fiscal year **2013**, and the related tax assessments have been finalized and settled.

The fiscal years **2014 to 2020** have been examined, and the related tax dispute is currently under review by the Internal Appeals Committee.

No documentary tax examination has been conducted for the fiscal years **2021 onwards**.

4. Sales Tax

The Company's tax records were examined for the period from the commencement of operations through the fiscal year **2015**, and the related tax assessments have been finalized and settled.

5. Value Added Tax (VAT)

The Company is registered for Value Added Tax ("VAT") in accordance with the provisions of **Law No. 67 of 2016**.

The Company's books and records have been examined for the fiscal years **2016 to 2022**, and the related tax assessments have been finalized and settled.

31- TAX POSITION (Continue)

The Company is currently preparing for the tax examination covering the period from **2023 to 2025**.

RAMEDA FOR PHARMACEUTICAL TRADING (S.A.E)

a) Corporate Tax

- The company provides legal procedures within the legal dates according to law 91 of year 2005.
- The years 2012 till 2021 have been inspected and the tax dues were paid and settled.

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The company has not been notified of the examination to now.

d) VAT

- The company was examined from the beginning of registration 8/2018 until 8/2019, and the tax dues were paid and settled.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

RAMECARE COMPANY (L.L.C.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No. 91 of 2005.
- The company was notified of a tax form (19) for the years 2015/2016/2017, and it was appealed
  on the legal date, and the necessary documents are being prepared for re-examination.
- The company was notified of a tax form (19) for the year 2019, and it was appealed on the legal date.
- The years from 2018 were not notified of the inspection.

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The years from the beginning of the activity until the year 2020, were inspected and settled

d) VAT

- The company has not been notified of the examination to now.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

31- TAX POSITION (CONTINUE)

RAMEPHARMA COMPANY (L.L.C.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No. 91 of 2005.
- The Company's records were inspected from year 2012 till the year 2021 and the due tax has been paid.
- Did not inspect from 2022 till now.

b) Salary Tax

- The company has not been notified of the examination to now.

31- TAX POSITION (CONTINUE)

c) Stamp Tax

- The company has not been notified of the examination to now.

d) VAT

- The company has not been notified of the examination to now.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

Glow Company (L.L.C.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No, 91 of 2005,
- Did not inspect till now.

b) Salary Tax

- The company has not been notified of the examination till now.

c) Stamp Tax

- The company has not been notified of the examination till now.

d) VAT

- The company has not been notified of the examination till now.

e) Withholding Tax

- The company has not been notified of the examination till now.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

32- RELATED PARTY DISCLOSURES

a) Due from related parties

For the purpose of these consolidated financial statements, parties are considered to be related to the Group, if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control.

	30 June 2026 EGP	*31 December 2025 EGP*
Eman Mohamed Wahed Mohamed El-Zomor - Ramepharma Co.	**12,750**	12,750
Eman Wahed Mohamed – Ramecare Co.	**12,750**	12,750
	25,500	25,500

b) **Salaries and incentives of key managers**

The key manager's compensation during period ended 30 June 2026 and 30 June 2025 is as follow:

	30 June 2026 EGP	*30 June 2025 EGP*
Salaries and incentives	**39,999,869**	33,735,091
Share options for employees, managers, and executives	**25,415,000**	-
	65,414,869	33,735,091

- No provisions charged for due from related parties.

33- CAPITAL MANAGMENT

For the purpose of the Company's capital management, capital includes issued capital and all other equity reserves attributable to the equity holders of Parent Company.

The primary objective of the Company's capital management is to maximize the shareholder value.

The Company manages its capital structure and makes adjustments in light of change in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company's monitors capital using a leverage ratio. Which is total liabilities divided by net equity. The Company's policy is to keep leverage ratio between 1 to 2.

34- FAIR VALUES OF FINANCIAL INSTRUMENTS

Financial instruments comprise financial assets and financial liabilities. Financial assets of the Company include cash on hand and at banks, trade and notes receivable, due from related parties and other receivables. Financial liabilities of the Company include credit facilities, trade and notes payable, dividends payable, income taxes payable, accrued expenses and other payables.

The fair values of the financial assets and liabilities are not materially different from their carrying value unless stated otherwise.

35- MAJOR EVENTS

The Monetary Policy Committee of the Central Bank of Egypt, in its meeting held on Thursday, 12 February 2026, decided to reduce the overnight deposit and lending rates, as well as the Central Bank's main operation rate, by 100 basis points, bringing them to 19%, 20%, and 19.5%, respectively. The Committee also decided to reduce the credit and discount rate by 100 basis points to 19.5%.

During the period ended 30 June 2026, certain regions in the Middle East experienced an escalation in geopolitical tensions, which had economic implications on regional markets and the Egyptian market. This resulted in an increase in the official exchange rate of foreign currencies against the Egyptian pound. Management has assessed the potential impact of these developments on the Company's operations, financial position, and results. Based on the information currently available, including the continued operation of core business activities, it is not practicable at this stage to reliably estimate the full financial impact of these unusual events on future periods. Management has also evaluated the extent to which these events may affect the Company's ability to continue as a going concern and concluded that the use of the going concern basis in preparing the financial statements remains appropriate.